Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

A cullin-RING ubiquitin ligase targets exogenous α-synuclein and inhibits Lewy body-like pathology.

Gerez JA, Prymaczok NC, Rockenstein E, Herrmann US, Schwarz P, Adame A, Enchev RI, Courtheoux T, Boersema PJ, Riek R, Peter M, Aguzzi A, Masliah E, Picotti P.

Sci Transl Med. 2019 Jun 5;11(495). pii: eaau6722. doi: 10.1126/scitranslmed.aau6722.

PMID:
31167929
2.

Early neuronal accumulation of DNA double strand breaks in Alzheimer's disease.

Shanbhag NM, Evans MD, Mao W, Nana AL, Seeley WW, Adame A, Rissman RA, Masliah E, Mucke L.

Acta Neuropathol Commun. 2019 May 17;7(1):77. doi: 10.1186/s40478-019-0723-5.

3.

NitroSynapsin for the treatment of neurological manifestations of tuberous sclerosis complex in a rodent model.

Okamoto SI, Prikhodko O, Pina-Crespo J, Adame A, McKercher SR, Brill LM, Nakanishi N, Oh CK, Nakamura T, Masliah E, Lipton SA.

Neurobiol Dis. 2019 Jul;127:390-397. doi: 10.1016/j.nbd.2019.03.029. Epub 2019 Mar 27.

PMID:
30928642
4.

Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.

Spencer B, Trinh I, Rockenstein E, Mante M, Florio J, Adame A, El-Agnaf OMA, Kim C, Masliah E, Rissman RA.

Neurobiol Dis. 2019 Jul;127:163-177. doi: 10.1016/j.nbd.2019.03.001. Epub 2019 Mar 5.

PMID:
30849508
5.

Effects of Novel Calpain Inhibitors in Transgenic Animal Model of Parkinson's disease/dementia with Lewy bodies.

Hassen GW, Kesner L, Stracher A, Shulman A, Rockenstein E, Mante M, Adame A, Overk C, Rissman RA, Masliah E.

Sci Rep. 2018 Dec 27;8(1):18083. doi: 10.1038/s41598-018-35729-1.

6.

Neuronal Exosome-Derived Human Tau is Toxic to Recipient Mouse Neurons in vivo.

Winston CN, Aulston B, Rockenstein EM, Adame A, Prikhodko O, Dave KN, Mishra P, Rissman RA, Yuan SH.

J Alzheimers Dis. 2019;67(2):541-553. doi: 10.3233/JAD-180776.

PMID:
30584143
7.

LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation.

Bae EJ, Kim DK, Kim C, Mante M, Adame A, Rockenstein E, Ulusoy A, Klinkenberg M, Jeong GR, Bae JR, Lee C, Lee HJ, Lee BD, Di Monte DA, Masliah E, Lee SJ.

Nat Commun. 2018 Aug 27;9(1):3465. doi: 10.1038/s41467-018-05958-z.

8.

Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation.

Kim C, Spencer B, Rockenstein E, Yamakado H, Mante M, Adame A, Fields JA, Masliah D, Iba M, Lee HJ, Rissman RA, Lee SJ, Masliah E.

Mol Neurodegener. 2018 Aug 9;13(1):43. doi: 10.1186/s13024-018-0276-2.

9.

Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders.

Spencer B, Brüschweiler S, Sealey-Cardona M, Rockenstein E, Adame A, Florio J, Mante M, Trinh I, Rissman RA, Konrat R, Masliah E.

Acta Neuropathol. 2018 Jul;136(1):69-87. doi: 10.1007/s00401-018-1869-0. Epub 2018 Jun 14.

PMID:
29934874
10.

Increased Vulnerability of the Hippocampus in Transgenic Mice Overexpressing APP and Triple Repeat Tau.

Arner A, Rockenstein E, Mante M, Florio J, Masliah D, Salehi B, Adame A, Overk C, Masliah E, Rissman RA.

J Alzheimers Dis. 2018;61(3):1201-1219. doi: 10.3233/JAD-170388.

11.

Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies.

Rockenstein E, Ostroff G, Dikengil F, Rus F, Mante M, Florio J, Adame A, Trinh I, Kim C, Overk C, Masliah E, Rissman RA.

J Neurosci. 2018 Jan 24;38(4):1000-1014. doi: 10.1523/JNEUROSCI.1170-17.2017. Epub 2017 Dec 15.

12.

Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype.

Minakaki G, Menges S, Kittel A, Emmanouilidou E, Schaeffner I, Barkovits K, Bergmann A, Rockenstein E, Adame A, Marxreiter F, Mollenhauer B, Galasko D, Buzás EI, Schlötzer-Schrehardt U, Marcus K, Xiang W, Lie DC, Vekrellis K, Masliah E, Winkler J, Klucken J.

Autophagy. 2018;14(1):98-119. doi: 10.1080/15548627.2017.1395992. Epub 2018 Jan 15.

13.

MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy.

Valera E, Spencer B, Mott J, Trejo M, Adame A, Mante M, Rockenstein E, Troncoso JC, Beach TG, Masliah E, Desplats P.

Front Mol Neurosci. 2017 Oct 17;10:329. doi: 10.3389/fnmol.2017.00329. eCollection 2017.

14.

Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology.

Ngolab J, Trinh I, Rockenstein E, Mante M, Florio J, Trejo M, Masliah D, Adame A, Masliah E, Rissman RA.

Acta Neuropathol Commun. 2017 Jun 9;5(1):46. doi: 10.1186/s40478-017-0445-5.

15.

Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.

El-Agnaf O, Overk C, Rockenstein E, Mante M, Florio J, Adame A, Vaikath N, Majbour N, Lee SJ, Kim C, Masliah E, Rissman RA.

Neurobiol Dis. 2017 Aug;104:85-96. doi: 10.1016/j.nbd.2017.05.002. Epub 2017 May 2.

16.

Distinct Pattern of Microgliosis in the Olfactory Bulb of Neurodegenerative Proteinopathies.

Kohl Z, Schlachetzki JC, Feldewerth J, Hornauer P, Münch M, Adame A, Riemenschneider MJ, Winkler J, Masliah E.

Neural Plast. 2017;2017:3851262. doi: 10.1155/2017/3851262. Epub 2017 Mar 19.

17.

The anticancer drug sunitinib promotes autophagyand protects from neurotoxicity in an HIV-1 Tat model of neurodegeneration.

Fields JA, Metcalf J, Overk C, Adame A, Spencer B, Wrasidlo W, Florio J, Rockenstein E, He JJ, Masliah E.

J Neurovirol. 2017 Apr;23(2):290-303. doi: 10.1007/s13365-016-0502-z. Epub 2017 Jan 19.

18.

Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.

Spencer B, Valera E, Rockenstein E, Overk C, Mante M, Adame A, Zago W, Seubert P, Barbour R, Schenk D, Games D, Rissman RA, Masliah E.

Acta Neuropathol Commun. 2017 Jan 13;5(1):7. doi: 10.1186/s40478-016-0410-8.

19.

Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy.

Valera E, Spencer B, Fields JA, Trinh I, Adame A, Mante M, Rockenstein E, Desplats P, Masliah E.

Acta Neuropathol Commun. 2017 Jan 5;5(1):2. doi: 10.1186/s40478-016-0409-1.

20.

Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans.

Chen SG, Stribinskis V, Rane MJ, Demuth DR, Gozal E, Roberts AM, Jagadapillai R, Liu R, Choe K, Shivakumar B, Son F, Jin S, Kerber R, Adame A, Masliah E, Friedland RP.

Sci Rep. 2016 Oct 6;6:34477. doi: 10.1038/srep34477.

21.

α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease.

Spencer B, Williams S, Rockenstein E, Valera E, Xin W, Mante M, Florio J, Adame A, Masliah E, Sierks MR.

Ann Clin Transl Neurol. 2016 Jun 16;3(8):588-606. doi: 10.1002/acn3.321. eCollection 2016 Aug.

22.

Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer's disease model.

Xu J, de Winter F, Farrokhi C, Rockenstein E, Mante M, Adame A, Cook J, Jin X, Masliah E, Lee KF.

Sci Rep. 2016 Aug 25;6:31692. doi: 10.1038/srep31692.

23.

Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model.

Spencer B, Desplats PA, Overk CR, Valera-Martin E, Rissman RA, Wu C, Mante M, Adame A, Florio J, Rockenstein E, Masliah E.

J Neurosci. 2016 Jul 27;36(30):7971-84. doi: 10.1523/JNEUROSCI.0775-16.2016.

24.

Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.

Price DL, Rockenstein E, Mante M, Adame A, Overk C, Spencer B, Duong-Polk KX, Bonhaus D, Lindsey J, Masliah E.

Sci Rep. 2016 Jul 8;6:29523. doi: 10.1038/srep29523.

25.

Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity.

Fields JA, Overk C, Adame A, Florio J, Mante M, Pineda A, Desplats P, Rockenstein E, Achim C, Masliah E.

J Neuroinflammation. 2016 May 24;13(1):120. doi: 10.1186/s12974-016-0585-8.

26.

Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease.

Rockenstein E, Clarke J, Viel C, Panarello N, Treleaven CM, Kim C, Spencer B, Adame A, Park H, Dodge JC, Cheng SH, Shihabuddin LS, Masliah E, Sardi SP.

Hum Mol Genet. 2016 Jul 1;25(13):2645-2660. Epub 2016 Apr 28.

27.

Possible Involvement of Adiponectin, the Anti-Diabetes Molecule, in the Pathogenesis of Alzheimer's Disease.

Waragai M, Adame A, Trinh I, Sekiyama K, Takamatsu Y, Une K, Masliah E, Hashimoto M.

J Alzheimers Dis. 2016 Apr 8;52(4):1453-9. doi: 10.3233/JAD-151116.

PMID:
27079710
28.

The HIV Protein gp120 Alters Mitochondrial Dynamics in Neurons.

Avdoshina V, Fields JA, Castellano P, Dedoni S, Palchik G, Trejo M, Adame A, Rockenstein E, Eugenin E, Masliah E, Mocchetti I.

Neurotox Res. 2016 May;29(4):583-593. doi: 10.1007/s12640-016-9608-6. Epub 2016 Mar 2.

29.

α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease.

Spencer B, Kim C, Gonzalez T, Bisquertt A, Patrick C, Rockenstein E, Adame A, Lee SJ, Desplats P, Masliah E.

Hum Mol Genet. 2016 Mar 15;25(6):1100-15. doi: 10.1093/hmg/ddv633. Epub 2016 Jan 5.

30.

Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson's disease.

Kim C, Ojo-Amaize E, Spencer B, Rockenstein E, Mante M, Desplats P, Wrasidlo W, Adame A, Nchekwube E, Oyemade O, Okogun J, Chan M, Cottam H, Masliah E.

J Neuroinflammation. 2015 Dec 18;12:236. doi: 10.1186/s12974-015-0455-9.

31.

Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease.

Spencer B, Potkar R, Metcalf J, Thrin I, Adame A, Rockenstein E, Masliah E.

J Biol Chem. 2016 Jan 22;291(4):1905-20. doi: 10.1074/jbc.M115.678185. Epub 2015 Nov 30.

32.

Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies.

Rockenstein E, Ubhi K, Mante M, Florio J, Adame A, Winter S, Brandstaetter H, Meier D, Masliah E.

BMC Neurosci. 2015 Nov 26;16:85. doi: 10.1186/s12868-015-0218-7.

33.

HIV alters neuronal mitochondrial fission/fusion in the brain during HIV-associated neurocognitive disorders.

Fields JA, Serger E, Campos S, Divakaruni AS, Kim C, Smith K, Trejo M, Adame A, Spencer B, Rockenstein E, Murphy AN, Ellis RJ, Letendre S, Grant I, Masliah E.

Neurobiol Dis. 2016 Feb;86:154-69. doi: 10.1016/j.nbd.2015.11.015. Epub 2015 Nov 22.

34.

Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy.

Kim C, Rockenstein E, Spencer B, Kim HK, Adame A, Trejo M, Stafa K, Lee HJ, Lee SJ, Masliah E.

Cell Rep. 2015 Oct 27;13(4):771-782. doi: 10.1016/j.celrep.2015.09.044. Epub 2015 Oct 17.

35.

A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy.

Spencer B, Valera E, Rockenstein E, Trejo-Morales M, Adame A, Masliah E.

Mol Neurodegener. 2015 Sep 23;10:48. doi: 10.1186/s13024-015-0043-6.

36.

Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis.

Zhao Y, Tseng IC, Heyser CJ, Rockenstein E, Mante M, Adame A, Zheng Q, Huang T, Wang X, Arslan PE, Chakrabarty P, Wu C, Bu G, Mobley WC, Zhang YW, St George-Hyslop P, Masliah E, Fraser P, Xu H.

Neuron. 2015 Sep 2;87(5):963-75. doi: 10.1016/j.neuron.2015.08.020.

37.

Neuro-peptide treatment with Cerebrolysin improves the survival of neural stem cell grafts in an APP transgenic model of Alzheimer disease.

Rockenstein E, Desplats P, Ubhi K, Mante M, Florio J, Adame A, Winter S, Brandstaetter H, Meier D, Masliah E.

Stem Cell Res. 2015 Jul;15(1):54-67. doi: 10.1016/j.scr.2015.04.008. Epub 2015 May 9.

38.

Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy.

Mandler M, Valera E, Rockenstein E, Mante M, Weninger H, Patrick C, Adame A, Schmidhuber S, Santic R, Schneeberger A, Schmidt W, Mattner F, Masliah E.

Mol Neurodegener. 2015 Mar 19;10:10. doi: 10.1186/s13024-015-0008-9.

39.

A novel triple repeat mutant tau transgenic model that mimics aspects of pick's disease and fronto-temporal tauopathies.

Rockenstein E, Overk CR, Ubhi K, Mante M, Patrick C, Adame A, Bisquert A, Trejo-Morales M, Spencer B, Masliah E.

PLoS One. 2015 Mar 24;10(3):e0121570. doi: 10.1371/journal.pone.0121570. eCollection 2015.

40.

Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disorders.

Fields JA, Dumaop W, Crews L, Adame A, Spencer B, Metcalf J, He J, Rockenstein E, Masliah E.

Curr HIV Res. 2015;13(1):43-54. Review.

41.

HIV-1 Tat alters neuronal autophagy by modulating autophagosome fusion to the lysosome: implications for HIV-associated neurocognitive disorders.

Fields J, Dumaop W, Eleuteri S, Campos S, Serger E, Trejo M, Kosberg K, Adame A, Spencer B, Rockenstein E, He JJ, Masliah E.

J Neurosci. 2015 Feb 4;35(5):1921-38. doi: 10.1523/JNEUROSCI.3207-14.2015. Erratum in: J Neurosci. 2015 May 27;35(21):8376. Elueteri, Simona [Corrected to Eleuteri, Simona].

42.

Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory.

Orr AG, Hsiao EC, Wang MM, Ho K, Kim DH, Wang X, Guo W, Kang J, Yu GQ, Adame A, Devidze N, Dubal DB, Masliah E, Conklin BR, Mucke L.

Nat Neurosci. 2015 Mar;18(3):423-34. doi: 10.1038/nn.3930. Epub 2015 Jan 26.

43.

Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an α-Synuclein Transgenic Model of Parkinson's Disease.

Rockenstein E, Desplats P, Ubhi K, Mante M, Florio J, Adame A, Winter S, Brandstaetter H, Meier D, Moessler H, Masliah E.

J Exp Neurosci. 2016 Jul 7;9(Suppl 2):131-40. doi: 10.4137/JEN.S25521. eCollection 2015.

44.

Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on α-synuclein.

Dhungel N, Eleuteri S, Li LB, Kramer NJ, Chartron JW, Spencer B, Kosberg K, Fields JA, Stafa K, Adame A, Lashuel H, Frydman J, Shen K, Masliah E, Gitler AD.

Neuron. 2015 Jan 7;85(1):76-87. doi: 10.1016/j.neuron.2014.11.027. Epub 2014 Dec 18. Erratum in: Neuron. 2015 Feb 4;85(3):657.

45.

Novel therapeutic strategy for neurodegeneration by blocking Aβ seeding mediated aggregation in models of Alzheimer's disease.

Eleuteri S, Di Giovanni S, Rockenstein E, Mante M, Adame A, Trejo M, Wrasidlo W, Wu F, Fraering PC, Masliah E, Lashuel HA.

Neurobiol Dis. 2015 Feb;74:144-57. doi: 10.1016/j.nbd.2014.08.017. Epub 2014 Aug 28.

46.

Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure.

Rockenstein E, Ubhi K, Trejo M, Mante M, Patrick C, Adame A, Novak P, Jech M, Doppler E, Moessler H, Masliah E.

BMC Neurosci. 2014 Jul 21;15:90. doi: 10.1186/1471-2202-15-90.

47.

Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.

Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, Patrick C, Ubhi K, Nuber S, Sacayon P, Zago W, Seubert P, Barbour R, Schenk D, Masliah E.

J Neurosci. 2014 Jul 9;34(28):9441-54. doi: 10.1523/JNEUROSCI.5314-13.2014.

48.

ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo.

Spencer B, Emadi S, Desplats P, Eleuteri S, Michael S, Kosberg K, Shen J, Rockenstein E, Patrick C, Adame A, Gonzalez T, Sierks M, Masliah E.

Mol Ther. 2014 Oct;22(10):1753-67. doi: 10.1038/mt.2014.129. Epub 2014 Jul 10.

49.

Silencing of murine transthyretin and retinol binding protein genes has distinct and shared behavioral and neuropathologic effects.

Buxbaum JN, Roberts AJ, Adame A, Masliah E.

Neuroscience. 2014 Sep 5;275:352-64. doi: 10.1016/j.neuroscience.2014.06.019. Epub 2014 Jun 21.

PMID:
24956283
50.

A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates Alzheimer disease pathology and restores neurogenesis.

Spencer B, Verma I, Desplats P, Morvinski D, Rockenstein E, Adame A, Masliah E.

J Biol Chem. 2014 Jun 20;289(25):17917-31. doi: 10.1074/jbc.M114.557439. Epub 2014 May 13.

Supplemental Content

Support Center